The safety profile of insulin compared to newer glycemic agents such as SGLT-2 inhibitors and GLP-1 analogs in advanced CKD need to be further examined in randomized controlled trials to determine optimal glycemic control therapy in this population. Here, SLC5A2 is linked to chronic kidney disease.